Abstract
Changes in the expression of xCT, the specific subunit of system xc(-) or the cystine/glutamate antiporter, have been associated with several neurological disorders and system xc(-) was recently proposed as a potential target for the development of new treatment strategies for multiple sclerosis (MS). In this study we used Theiler's murine encephalomyelitis virus (TMEV) infection, both in vitro and in vivo, as a model to further evaluate the involvement of system xc(-) in MS. Protein levels of xCT, as well as activity of system xc(-) were unaffected in RAW264.7 macrophages after infection with the demyelinating DA strain of TMEV. Also, protein expression of xCT remained stable in spinal cord and brain of FVB mice 1-2 and 6 weeks after intracranial injection of the DA strain of TMEV. These results demonstrate that TMEV infection of macrophages or FVB mice has no effect on system xc(-) and as such cannot be used as a model to study the involvement of system xc(-) in MS.
References
Sep 1, 1978·Cell·W C RaschkeI Nakoinz
Sep 1, 1995·The Biochemical Journal·H SatoS Bannai
Sep 12, 2000·Journal of Virology·O van Eyll, T Michiels
Dec 19, 2000·Virology·J R ChangE L Oleszak
Oct 29, 2003·Neurology·David PittCedric S Raine
Oct 14, 2004·Journal of Virology·Wenan QiangPaul K Y Wong
Sep 8, 2005·The Journal of Biological Chemistry·Hideyo SatoShiro Bannai
Mar 24, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Si QinMichel Mallat
May 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Sophie DelhayeThomas Michiels
Jun 15, 2006·Journal of Neurochemistry·Jan LewerenzAxel Methner
Feb 22, 2008·Virology·Pamela A CarpentierStephen D Miller
Sep 23, 2008·Neuroreport·Ann MassieYvette Michotte
Jun 7, 2011·Journal of Neuroinflammation·Olatz PampliegaCarlos Matute
Mar 2, 2012·Current Neuropharmacology·Ingrid Loma, Rock Heyman
Nov 6, 2012·European Journal of Pharmacology·Ankita MehtaP L Sharma